http://orcid.org/0000-0002-6556-4128
References
- Negro A, Curto M, Lionetto L, et al. Martelletti P Chronic migraine treatment: from onabotulinumtoxinA onwards. Expert Rev Neurother. 2016;16:1217–1227.
- Giamberardino MA, Martelletti P. Emerging drugs for migraine treatment. Expert Opin Emerg Drugs. 2015;20:137–147.
- Giamberardino MA, Affaitati G, Curto M, et al. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11:1045–1057.
- Capi M, de Andrés F, Lionetto L, et al. Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017;26:227–234.
- Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. Nat Rev Neurol. 2016;12:635–650.
- Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11:175–177.
- Lecchi M, D’Alonzo L, Negro A, et al. Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. Expert Opin Drug Metab Toxicol. 2014;10:1381–1395.
- Macone A, Perloff MD. Triptans and migraine: advance in use, administration, formulation, and development. Exp Opin Pharmacoter. 2017;18:387–397.
- Capi M, Curto M, Lionetto L, et al. Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016;9:414–423.
- Lionetto L, Borro M, Curto M, et al. Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2016;12:399–406.
- Affaitati G, Martelletti P, Lopopolo M, et al. Use of nonsteroidal anti-inflammatory drugs for symptomatic treatment of episodic headache. Pain Pract. 2017;17:392–401.
- Xu H, Han W, Wang J, et al. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain. 2016;17:113.
- Cevoli S, D’Amico D, Martelletti P, et al. Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia. 2009;29:1285–1293.
- Eyre BL, Eadie MJ, van Driel ML, et al. Triptan use in Australia 1997–2015: a pharmacoepidemiological study. Acta Neurol Scand. 2017 Jan 16. doi: 10.1111/ane.12727. [Epub ahead of print]
- Thorlund K, Sun-Edelstein C, Druyts E, et al. Risk of medication overuse headache across classes of treatments for acute migraine. J Headache Pain. 2016;17:107.
- Negro A, Martelletti P. Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain. 2011;12:593–601.
- [Cited 15 March 2017]. www.clinicaltrials.gov
- Martelletti P, Curto M. Headache: cluster headache treatment – RCTs versus real-world evidence. Nat Rev Neurol. 2016;12:557–558.
- Ayata C. Migraine: treasure hunt in a minefield – exploring migraine with GWAS. Nat Rev Neurol. 2016;12:496–498.
- Zhang LM, Dong Z, Yu SY. Migraine in the era of precision medicine. Ann Transl Med. 2016;4:105.
- Steiner TJ, Stovner LJ, Vos TGBD. 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17:104.
- Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361–378.